Anonymous v Bayer: Incentive scheme materials implied call targets that could breach the ABPI limit on unsolicited representative calls (AUTH/2533/10/12)

📅 2012 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/2533/10/12
PartiesAnonymous v Bayer
IssueRepresentative call rates; incentive scheme materials potentially encouraging excessive unsolicited calls
Complaint received11 October 2012
Case completed27 November 2012
Applicable Code year2012
MaterialsPresentations emailed to representatives: “Incentive Scheme H2 2012” (ref UK.PH.GM.2012.057) and “Consolidation Objectives for H2” (ref UK.PH.GM.2012.055); later FAQ certified 27 September (ref UK.PH.GM.2012.079)
Panel findingsBreach Clauses 9.1 and 15.9; No breach Clauses 2 and 15.4
AppealNo appeal
SanctionsUndertaking received; additional sanctions not stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous complainant (appearing to be a Bayer employee) alleged Bayer HealthCare’s H2 2012 incentive scheme encouraged representatives to make three calls/visits on all target customers in the second half of the year regardless of earlier activity.
  • Slides from the incentive scheme presentation were provided, showing bonus-linked “frequency activity scale” targets (eg percentages of target customers seen three times).
  • Bayer had emailed two presentations to representatives: Incentive Scheme H2 2012 and Consolidation Objectives for H2, plus a covering email emphasising maximising time in territory and number of target customers seen.
  • Neither the covering email nor the H2 incentive presentation explicitly referenced the ABPI Code requirements on call frequency; the “terms and conditions” slide referred back to H1 terms.
  • Bayer relied on initial training and an internal SOP stating “Calls are proactive – no more than 3 per [health professional] per year”, and later produced an FAQ (certified late September) clarifying “within the limit of 3 unsolicited calls per year”.
  • The Panel stressed the Code expectation that briefing material should distinguish between expected call rates and contact rates, and that targets must be realistic and not drive breaches.
⚖️

Outcome

  • Breach of Clause 15.9: the incentive scheme material was found to advocate a course of action likely to breach the Code.
  • Breach of Clause 9.1: by advocating a course of action likely to breach the Code, the material did not maintain a high standard.
  • No breach of Clause 15.4: no evidence was provided that call frequency caused inconvenience to health professionals.
  • No breach of Clause 2: despite serious concern, the Panel decided the circumstances did not warrant the particular censure of Clause 2.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training